Anavex Commences Trading on NASDAQ Today – To Ring Friday’s Closing Bell
NEW YORK, NY – October 28, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, is pleased to announce that it will begin trading its common stock on the Nasdaq Capital Market today at the opening of market hours under the symbol “AVXL.”
The company’s management team also has the privilege of ringing the Nasdaq Closing Bell on Friday, October 30, 2015. This historic occasion for the Company can be viewed at 4:00 p.m. ET via live webcast at https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx. It will also be archived for investors who are unable to view the bell ringing as a live stream or on participating TV networks, including CNBC, Bloomberg TV and Fox Business News.
“This is a significant milestone for Anavex. We are extremely honored to ring the Closing Bell this coming Friday to celebrate Anavex’s start of trading on the Nasdaq Capital Market,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We thank our shareholders for their ongoing support and look forward to reaching a broader audience of institutions, funds and retail investors around the world.”
About Anavex™ Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. Initial positive data was presented at AAIC 2015 and full PART A and preliminary PART B Phase 2a clinical trial data will be presented at CTAD in November 2015. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties indicating its potential to treat additional CNS disorders. Further information is available at www.anavex.com.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information
Anavex™ Life Sciences Corp.
Research & Business Development